Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Natalie Bradford

Physician Assistant, Medical Benton, AR Physician Assistant

NPI 1558657999 CMS profile 11221264

819 W Carpenter St, Benton, AR 72015

Open in the dashboard

General payments

$4,475

271 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Natalie Bradford of Benton, AR is reported in the CMS Open Payments database as having received $4,475 across 271 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 87th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $875 49
2024 General $899 53
2023 General $730 44
2022 General $914 57
2021 General $1,056 68

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Natalie Bradford
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Natalie Bradford were reported at $875. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Natalie Bradford Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $1,056 $156 $41–$563 $132
2022 $914 $185 $55–$649 $149
2023 $730 $199 $58–$717 $160
2024 $899 $206 $62–$740 $164
2025 $875 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Pfizer Inc. $593 38 payments
  2. Amgen Inc. $570 33 payments
  3. AbbVie, Inc. $510 34 payments
  4. Abbott Laboratories $291 14 payments
  5. Lilly USA, LLC $286 21 payments
  6. Otsuka America Pharmaceutical, Inc. $272 14 payments
  7. Salix Pharmaceuticals, a division of Bausch Health US, LLC $217 11 payments
  8. Novo Nordisk Inc $179 11 payments
  9. Amarin Pharma Inc. $142 9 payments
  10. Exact Sciences Corporation $139 9 payments
  11. Other $1,274 77 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $4,475 271 payments
Products named General payments · program years 2021–2025
  1. AIMOVIG $363 20 payments
  2. NURTEC ODT $302 18 payments
  3. REXULTI $272 14 payments
  4. ZAVZPRET $220 13 payments
  5. XIFAXAN $217 11 payments
  6. Otezla $207 13 payments
  7. UBRELVY $200 12 payments
  8. QULIPTA $196 15 payments
  9. VRAYLAR $195 12 payments
  10. Repatha $193 13 payments
  11. Other $3,659 227 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 94 drugs

Part D claims

4,283

Median for Physician Assistant: 241

Drug cost

$249,534

Median for Physician Assistant: $4,110

Branded share of claims

20.1%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trulicity Dulaglutide Brand 35 $45,958
Jardiance Empagliflozin Brand 40 $29,870
Mounjaro Tirzepatide Brand 20 $26,088
Ozempic Semaglutide Brand 14 $21,726
Repatha Sureclick Evolocumab Brand 24 $14,388
Tresiba Flextouch U-200 Insulin Degludec Brand 14 $13,279
Xarelto Rivaroxaban Brand 12 $12,620
Tradjenta Linagliptin Brand 16 $11,068
Anoro Ellipta Umeclidinium Brm/Vilanterol Tr Brand 18 $10,699
Linzess Linaclotide Brand 13 $8,130

The 10 drugs with the highest cost, of 94 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 50 billing codes

Paid by Medicare

$37,171

Of which drugs: $5,648

Medicare patients

200

Average age 74

Services billed

1,856

132 women, 68 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 73%
Arthritis 42%
Ischemic heart disease 31%
Diabetes 25%
Depression 23%
Atrial fibrillation 19%
Cancer 18%
COPD 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90662 Office 31 31 $2,527
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 34 160 $103
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 34 160 $12

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 21 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
REXULTI
  • Otsuka America Pharmaceutical, Inc. $96
  • Lundbeck LLC $54
$150 — —
MOUNJARO
  • Lilly USA, LLC $79
$79 20 —
NURTEC ODT
  • PFIZER INC. $69
$69 — —
ZAVZPRET
  • PFIZER INC. $53
$53 — —
VRAYLAR
  • AbbVie, Inc. $50
$50 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 21 in the dashboard with a free account

Records

271 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Arkansas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record